Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y4F9
UPID:
RIPR2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y4F9; A6NHP2; Q13529; Q5VV37; Q5VV38; Q9BQ28
Background:
Rho family-interacting cell polarization regulator 2 plays a pivotal role in cellular processes including myoblast and hair cell differentiation, T lymphocyte proliferation, and neutrophil polarization. It acts as an inhibitor of the small GTPase RHOA, influencing cell adhesion, polarization, and migration. This protein is essential for the normal development of cochlear hair cells and for maintaining the structural integrity of stereocilia, crucial for hearing.
Therapeutic significance:
Given its critical role in hearing and immune cell function, targeting Rho family-interacting cell polarization regulator 2 could offer novel therapeutic avenues for treating autosomal recessive and dominant forms of non-syndromic sensorineural hearing loss. Understanding the role of this protein could open doors to potential therapeutic strategies.